Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ripertamab - Sinocelltech

Next Previous
Drug Profile

Ripertamab - Sinocelltech

Alternative Names: Recombinant chimeric anti-CD20 monoclonal antibody - Sinocelltech; SCT-400

Latest Information Update: 12 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sinocelltech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoprotein stimulants; Apoptosis stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Diffuse large B cell lymphoma
  • Phase III Non-Hodgkin's lymphoma

Most Recent Events

  • 05 Feb 2026 Sinocelltech plans a clinical trial for the treatment of Nephrotic-syndrome (In adolescents, In children, In infants) in China, in February 2026 (NCT07388810)
  • 28 Jan 2026 Zhongming Qiu in collaboration with Sinocelltech plans a phase I/II RIPERT-MG trial for Myasthenia Gravis (IV, Infusion) in February 2026 (NCT07372807)
  • 15 Mar 2025 Sinocelltech plans a phase III RIPERT-CIDP trial for Chronic Inflammatory Demyelinating Polyneuropathy in March 2025 (IV) (NCT06858722)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top